Twirla® (levonorgestrel/ethinyl estradiol)
Contraception
ApprovedCommercial
Key Facts
About Agile Therapeutics
Agile Therapeutics is a commercial-stage biopharmaceutical company dedicated to providing women with expanded contraceptive options. The company's primary asset is Twirla, a hormonal contraceptive patch utilizing its Skinfusion® transdermal technology, which represents its first approved product. Founded in 1997 and headquartered in Princeton, New Jersey, Agile is publicly traded and operates in the small molecules sector. Its pipeline and commercial strategy are centered on leveraging its proprietary patch platform to address unmet needs in women's health.
View full company profileTherapeutic Areas
Other Contraception Drugs
| Drug | Company | Phase |
|---|---|---|
| Drosperinone + Ethinyl Estradiol Tablets | BDR Pharmaceuticals | Commercial |
| Gen II FemCap Commercialization | FemCap | Approved |
| Eucontra | Hera Health Solutions | Filed |
| 3Daughters IUD | 3Daughters | Pre-clinical |
| Copper 175 mm² IUD | Sebela Pharmaceuticals | Phase 3 |
| SiRx‑Contraception | SiCare Bio | Discovery |
| Novel Oral Contraceptive Combinations | RPG Life Sciences | Formulation Development |
| AYA™ (etonogestrel) contraceptive vaginal system | Organon | Filed |